Showing 1 - 10 of 31 Other
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator: Valentina Villarroel

Phone: 346.238.4384

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator: Valentina Villarroel

Phone: 346.238.4384

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator:

Phone:

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the effectiveness and safety of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in 2019 Coronavirus Disease (COVID-19) patien ... Read more >

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >

A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Status: Enrolling

Investigator: Michael Klebuc

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room. The main purposes of this study are to 1) see how safe NTX-001 is when used in nerv ... Read more >

A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias treated Robotically with OviTex® Reinforced Tissue Matrix

Status: Open Not Enrolling

Investigator: Nabil Tariq

Study Coordinator:

Phone:

This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.</ ... Read more >

A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2/fibrosis 3 stage of liver fibrosis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (TROPOS Study)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Cassidy Smith

Phone: 713.441.4106

Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy. The study is divided into ... Read more >

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Status: Enrolling

Investigator: Eamonn Quigley

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participa ... Read more >

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Status: Enrolling

Investigator: Eamonn Quigley

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the effi ... Read more >

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease. BI 706321 is a medicine being dev ... Read more >

ABTECT - Maintenance

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequa ... Read more >

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequat ... Read more >

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice. ... Read more >

An Open-label, Phase II, Pre-operative Study of Atezolizumab plus Bevacizumab for Resectable Hepatocellular Carcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for ... Read more >

Auxora for the Treatment of AKI and Modulation of Injurious “Crosstalk” with the Lung: A Randomized Control Trial (KOURAGE)

Status: Open Not Enrolling

Investigator: Raul Sanchez Leon

Study Coordinator: Hira Saleem

Phone: 346.238.0307

Acute kidney injury (AKI) describes a sudden decrease in the glomerular filtration rate and is clinically diagnosed by an increase in serum creatinine and/or a decrease in urine output. An increase in serum creatinine of either = 0.3 mg/dL withi ... Read more >

Corrona Inflammatory Bowel Disease (IBD) Registry

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

NMDA Receptor in Psychosis: Specific Auto-Antibodies

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator:

Phone:

Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >

Ocrelizumab for Psychosis by Autoimmunity (OPA)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

Status: Enrolling

Investigator: Masayoshi Takashima

Study Coordinator: Tariq Syed

Phone: 346.238.6466

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare aFixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea. ... Read more >

Phase 2, Randomized Double-Blind Double-Dummy Placebo-Controlled Study Testing the Safety & Efficacy of Semaglutide, & the Fixed-Dose Combination of Cilofexor & Firsocostat, Alone & in Combination, in Subjects with Compensated Cirrhosis (F4) due to NASH

Status: Enrolling

Investigator: David Victor

Study Coordinator: Lindsay Barter

Phone: 502.417.6664

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steat ... Read more >

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Nilsa Nunez

Phone: 713.441.7182

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). In this study, subjects will undergo a broad ran ... Read more >

Randomized Controlled Trial Comparing NEUROMARK System to Sham Control in Patients With Chronic Rhinitis

Status: Enrolling

Investigator: Masayoshi Takashima

Study Coordinator: Tariq Syed

Phone: 346.238.6466

The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial. ... Read more >

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Status: Enrolling

Investigator: Masayoshi Takashima

Study Coordinator: Tariq Syed

Phone: 346.238.6466

The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064. The study will take approximately 32 weeks which will ... Read more >

REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

Status: Enrolling

Investigator: Christopher Fan

Study Coordinator: Davesia Tenner

Phone: 346.238.4820

This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe ... Read more >

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Ana Lucia Varon Ocampo

Phone: 713.441.7182

Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Ana Lucia Varon Ocampo

Phone: 713.441.7182

Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >

The Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)

Status: Enrolling

Investigator: David Victor

Study Coordinator: Miguel Valdivia y Alvarado

Phone: 346.238.2626

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which t ... Read more >

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

Status: Open Not Enrolling

Investigator: Laila Tabatabai

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >